Treatment of multiple myeloma: An emphasis on new developments

References

• Kyle R. A., Gertz M. A., Witzig T. E., Lust J. A., Lacy M. Q., Dispenzieri A., et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21–33
   PubMed Web of Science ®Google Scholar
• Kyle R. A., Rajkumar S. V. Multiple myeloma. N Engl J Med 2004; 351: 1860–73, Erratum in: N Engl J Med. 2005;352:1163
   PubMed Web of Science ®Google Scholar
• Kyle R. A., Therneau T. M., Rajkumar S. V., Offord J. R., Larson D. R., Plevak M. F., et al. A long‐term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 564–9
   PubMed Web of Science ®Google Scholar
• Kyle R. A., Greipp P. R. Smoldering multiple myeloma. N Engl J Med 1980; 302: 1347–9
   PubMed Web of Science ®Google Scholar
• Cavo M., Zamagni E., Tosi P., Tacchetti P., Cellini C., Cangini D., et al. Superiority of thalidomide and dexamethasone over vincristine‐doxorubicin‐dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005 Jul; 106: 35–9, Epub 2005 Mar 10
   PubMed Web of Science ®Google Scholar
• Rajkumar S. V., Blood E., Vesole D. H., Shepard R., Greipp P. R. Thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed multiple myeloma (E1A00): results of a phase III trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood 2004; 104: 63a
   Google Scholar
• Attal M., Harousseau J. L., Stoppa A. M., Sotto J. J., Fuzibet J. G., Rossi J. F., et al. Intergroupe Francais du Myelome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91–7
   PubMed Web of Science ®Google Scholar
• Child J. A., Morgan G. J., Davies F. E., Owen R. G., Bell S. E., Hawkins K., et al. Medical Research Council Adult Leukaemia Working Party. High‐dose chemotherapy with hematopoietic stem‐cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–83
   PubMed Web of Science ®Google Scholar
• Moreau P., Facon T., Attal M., Hulin C., Michallet M., Maloisel F., et al. Intergroupe Francophone du Myelome. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731–5
   PubMed Web of Science ®Google Scholar
• Attal M., Harousseau J. L., Facon T., Guilhot F., Doyen C., Fuzibet J. G., et al. InterGroupe Francophone du Myelome. Single versus double autologous stem‐cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–502, Erratum in: N Engl J Med. 2004;350:2628
   PubMed Web of Science ®Google Scholar
• Stewart A. K., Vescio R., Schiller G., Ballester O., Noga S., Rugo H., et al. Purging of autologous peripheral‐blood stem cells using CD34 selection does not improve overall or progression‐free survival after high‐dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001; 19: 3771–9
   PubMed Web of Science ®Google Scholar
• Maloney D. G., Molina A. J., Sahebi F., Stockerl‐Goldstein K. E., Sandmaier B. M., Bensinger W., et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003 Nov 1; 102: 3447–54, Epub 2003 Jul 10
   PubMed Web of Science ®Google Scholar
• Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998; 16: 3832–42
   PubMed Web of Science ®Google Scholar
• Kumar S. K., Therneau T. M., Gertz M. A., Lacy M. Q., Dispenzieri A., Rajkumar S. V., et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004; 79: 867–74
   PubMed Web of Science ®Google Scholar
• Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–71, Erratum in: N Engl J Med. 2000;342:364
   PubMed Web of Science ®Google Scholar
• Barlogie B., Desikan R., Eddlemon P., Spencer T., Zeldis J., Munshi N., et al. Extended survival in advanced and refractory multiple myeloma after single‐agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492–4
   PubMed Web of Science ®Google Scholar
• Dimopoulos M. A., Anagnostopoulos A., Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol 2003; 21: 4444–54
   PubMed Web of Science ®Google Scholar
• Richardson P. G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–17
   PubMed Web of Science ®Google Scholar
• Richardson P. G., Sonneveld P., Schuster M. W., Irwin D., Stadtmauer E. A., Facon T., et al. Bortezomib or high‐dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–98
   PubMed Web of Science ®Google Scholar
• Hideshima T., Anderson K. C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002; 2: 927–37
   PubMed Web of Science ®Google Scholar
• Hideshima T., Chauhan D., Podar K., Schlossman R. L., Richardson P., Anderson K. C. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001; 28: 607–12
   PubMed Web of Science ®Google Scholar
• Munshi N. C. Arsenic trioxide: an emerging therapy for multiple myeloma. Oncologist 2001; 6 Suppl 2: 17–21
   Google Scholar
• Shaughnessy J., Jr. Primer on medical genomics part IX: scientific and clinical applications of DNA microarrays: multiple myeloma as a disease model. Mayo Clin Proc 2003; 78: 1098–109
   PubMed Web of Science ®Google Scholar